Vivian Chua

459 total citations
17 papers, 326 citations indexed

About

Vivian Chua is a scholar working on Molecular Biology, Ophthalmology and Oncology. According to data from OpenAlex, Vivian Chua has authored 17 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Ophthalmology and 7 papers in Oncology. Recurrent topics in Vivian Chua's work include Ocular Oncology and Treatments (13 papers), Ubiquitin and proteasome pathways (6 papers) and Cancer-related Molecular Pathways (5 papers). Vivian Chua is often cited by papers focused on Ocular Oncology and Treatments (13 papers), Ubiquitin and proteasome pathways (6 papers) and Cancer-related Molecular Pathways (5 papers). Vivian Chua collaborates with scholars based in United States, Australia and South Korea. Vivian Chua's co-authors include Andrew E. Aplin, Timothy J. Purwin, Takami Sato, Philip Wedegaertner, Jeffrey Benovic, Mizue Terai, Anna Han, Richard D. Carvajal, Michael A. Davies and Gary K. Schwartz and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and Oncogene.

In The Last Decade

Vivian Chua

17 papers receiving 323 citations

Peers

Countries citing papers authored by Vivian Chua

Since Specialization

Citations

This map shows the geographic impact of Vivian Chua's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivian Chua with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivian Chua more than expected).

Fields of papers citing papers by Vivian Chua

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vivian Chua. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivian Chua. The network helps show where Vivian Chua may publish in the future.

Co-authorship network of co-authors of Vivian Chua

This figure shows the co-authorship network connecting the top 25 collaborators of Vivian Chua. A scholar is included among the top collaborators of Vivian Chua based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vivian Chua. Vivian Chua is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress 2024 ·Science Signaling ·Vivian Chua, (unknown), Mizue Terai, Ryota Tanaka, (unknown), Timothy J. Purwin, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Anna Han, Inna Chervoneva, Michael A. Davies, Julio A. Aguirre‐Ghiso, Takami Sato, Andrew E. Aplin	2
2	Metabolic Inhibition Induces Pyroptosis in Uveal Melanoma 2024 ·Molecular Cancer Research ·Scott Varney, Dan A. Erkes, (unknown), (unknown), Vivian Chua, Inna Chervoneva, Timothy J. Purwin, Emad S. Alnemri, Andrew E. Aplin	4
3	Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth 2023 ·Cancers ·Anna Han, Dzmitry Mukha, Vivian Chua, Timothy J. Purwin, Manoela Tiago, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Mizue Terai, Philip Wedegaertner, Takami Sato, Solange Landreville, Michael A. Davies, Stefan Kurtenbach, J. William Harbour, Zachary T. Schug, Andrew E. Aplin	5
4	Abstract A009: NR2F1 inhibits Gaq/11-YAP-TAZ signaling and limits reactivation of uveal melanoma disseminated cancer cells via induction of dormancy 2023 ·Cancer Research ·(unknown), (unknown), Vivian Chua, Timothy J. Purwin, (unknown), Andrew E. Aplin, Julio A. Aguirre‐Ghiso	1
5	Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma 2023 ·Journal of Biological Chemistry ·(unknown), Alison Kurimchak, (unknown), Timothy J. Purwin, (unknown), Anna Han, (unknown), (unknown), (unknown), Vivian Chua, Michael A. Davies, J. Silvio Gutkind, Jeffrey Benovic, James S. Duncan, Andrew E. Aplin	2
6	Multi-omics Profiling Shows BAP1 Loss Is Associated with Upregulated Cell Adhesion Molecules in Uveal Melanoma 2022 ·Molecular Cancer Research ·(unknown), Timothy J. Purwin, (unknown), Vivian Chua, Anna Han, Edward J. Hartsough, (unknown), J. William Harbour, Andrew E. Aplin	15
7	The AMP‐dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma 2021 ·Pigment Cell & Melanoma Research ·Vivian Chua, Anna Han, (unknown), Timothy J. Purwin, (unknown), (unknown), J. William Harbour, Andrew E. Aplin	13
8	Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma 2020 ·Molecular Cancer Therapeutics ·Jessica L.F. Teh, Timothy J. Purwin, Anna Han, Vivian Chua, Prem Patel, (unknown), (unknown), (unknown), Takami Sato, Michael A. Davies, Julio A. Aguirre‐Ghiso, Andrew E. Aplin	18
9	BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors 2020 ·Oncogene ·Anna Han, Timothy J. Purwin, (unknown), (unknown), Vivian Chua, Erin L. Seifert, Takami Sato, Zachary T. Schug, David W. Speicher, J. William Harbour, Andrew E. Aplin	32
10	The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019) 2020 ·Clinical Cancer Research ·Vivian Chua, Jane Mattei, Anna Han, (unknown), (unknown), (unknown), Richard D. Carvajal, Andrew E. Aplin, Sapna P. Patel	16
11	Inhibition of NF-κB–Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma 2019 ·Cancer Research ·Grazia Ambrosini, Catherine Do, Benjamin Tycko, Ronald Realubit, Charles Karan, Elgilda Musi, Richard D. Carvajal, Vivian Chua, Andrew E. Aplin, Gary K. Schwartz	34
12	Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma 2019 ·EMBO Molecular Medicine ·Vivian Chua, Marlana Orloff, Jessica L.F. Teh, Takahito Sugase, (unknown), Timothy J. Purwin, Bao Lam, Mizue Terai, Grazia Ambrosini, Richard D. Carvajal, Gary K. Schwartz, Takami Sato, Andrew E. Aplin	47
13	Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma 2017 ·Molecular Cancer Therapeutics ·Hanyin Cheng, Vivian Chua, (unknown), Timothy J. Purwin, Mizue Terai, Ken Kageyama, Michael A. Davies, Takami Sato, Andrew E. Aplin	54
14	Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma 2017 ·Molecular Cancer Research ·Vivian Chua, (unknown), (unknown), Jeffrey Benovic, Philip Wedegaertner, Andrew E. Aplin	65
15	Novel therapeutic strategies and targets in advanced uveal melanoma 2017 ·Current Opinion in Oncology ·Vivian Chua, Andrew E. Aplin	11
16	Activity of ABCG2 Is Regulated by Its Expression and Localization in DHT and Cyclopamine‐Treated Breast Cancer Cells 2016 ·Journal of Cellular Biochemistry ·Vivian Chua, Irma Larma, Jennet Harvey, Marc A. Thomas, Jacqueline M. Bentel	6
17	Abstract 715: Regulation of the ABCG2 drug efflux transporter in breast cancer cells 2015 ·Cancer Research ·Vivian Chua, Jennet Harvey, Jacqueline M. Bentel	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact